-
Article
hTERT: a novel endogenous inhibitor of the mitochondrial cell death pathway
hTERT is the catalytic subunit of the telomerase and is hence required for telomerase maintenance activity and cancer cell immortalization. Here, we show that acute hTERT depletion has no adverse effects on th...
-
Article
Actualités de l’ASCO 2006
Les thérapies moléculaires ciblées ont modifié les stratégies de traitements de plusieurs cancers et ouvrent de nouvelles perspectives dans la prise en charge des patients. Cette année, deux études de phase II...
-
Article
Inhibiteurs de tyrosine kinase ciblant le VEGFR
L'angiogénèse est un mécanisme central dans le processus de croissance tumorale et de métastases. La famille du VEGF et des récepteurs au VEGF est un des régulateurs les plus importants de l'angiogenèse. Diffé...
-
Article
Open AccessCarcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
Carcinomas of an unknown primary site (CUP) are heterogeneous tumours with a median survival of only 8 months. Tyrosine kinase inhibitors are promising new drugs. The aim of this study was to determine the exp...
-
Article
Autogreffe dans les cancers du testicule
Les patients atteints de tumeurs germinales sont en grande majorité guéris par le traitement de chimiothérapie à base de platine et la chirurgie des masses résiduelles. Cependant, le groupe de patients de mauv...
-
Article
Open AccessErratum: Carcinoma of an unknown primary: are EGF receptor, Her-2/neu, and c-Kit tyrosine kinases potential targets for therapy?
Correction to: British Journal of Cancer (2008) 97, 857–861, doi:10.1038/sj.bjc.6603942 The authors of the above paper, first published in October 2007, would like to add the following acknowledgement to their...
-
Article
Chimiothérapie des CAPI: quelles leçons peut-on en tirer en 2008 ?
Chemotherapy is the backbone of treatment forpatients with CUP. Most patients with unknown primary adenocarcinoma or poorly differentiated carcinoma do not conform to any previously defined “treatable” or favo...
-
Article
Rhinitis and epistaxis in patients treated by anti-angiogenic therapy
Anti-angiogenic therapies have a particular drug-related toxicity profile including hypertension, thrombosis, haemorrhages, and proteinuria. Moreover, patients treated by angiogenesis inhibitors present nasal ...
-
Article
Open AccessA phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours
Sunitinib is a multitargeted, oral tyrosine kinase inhibitor with antitumour and antiangiogenic activity. We investigated the safety and pharmacokinetics of sunitinib in combination with irinotecan in patients...
-
Article
Open AccessA direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas
Circulating tumour cells (CTCs) can provide information on patient prognosis and treatment efficacy. However, there is no universal method to detect CTC currently available. Here, we compared the performance o...
-
Article
Les thérapies ciblées de l’os métastatique: soins de support ou traitements de fond ?
Bone metastases in prostate cancer treatment stand as a clinical challenge in order to maintain quality of life and prevent pain and skeletal-related events. Bone metastases predominantly disrupts the dynamic ...
-
Article
Agents antiangiogéniques et association de TMC: attention danger
Greater knowledge in cancer biology has led to the isolation of molecular targets implicated in cell physiology. New treatments blocking a specific molecular target, in particular compounds blocking kinase act...
-
Article
Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumors
Background ES-285 (spisulosine) is a novel compound derived from the marine mollusk Spisula polynoma with evidence of preclinical antitumor activity. This phase I clinical trial was designed to i...
-
Article
Erratum: hTERT: a novel endogenous inhibitor of the mitochondrial cell death pathway
Correction to: Oncogene (2006) 25, 4505–4514; doi:10.1038/sj.onc.1209487; published online 17 April 2006 Errors were inadvertently included in Figure 3a of the article mentioned above. In particular, represent...
-
Article
Cibler le métabolisme tumoral : efficacité et perspectives
Metabolic reprogramming is a hallmark of cancer which will provide tumor cells with all metabolites needed for growth and proliferation. Numerous oncogenes are responsible for a cellular metabolic reprogrammin...
-
Article
A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma
Background The kinesin spindle protein Eg5 is involved in mitosis, and its inhibition promotes mitotic arrest. EMD 534085, a potent, reversible Eg5 inhibitor, demonstrated significant pre...
-
Article
Les tumeurs germinales de stade métastatique
Les tumeurs du testicule sont les cancers les plus fréquents de l’homme jeune. Depuis les années 1970, les tumeurs germinales métastatiques sont devenues le paradigme des cancers curables par l’utilisation de ...
-
Article
Who dies from prostate cancer?
During the last 30 years, there has been a major shift in initial staging in prostate cancer (CaP) in Western countries, with the incidence of metastases at diagnosis decreasing from over 50% in the 1970s to c...
-
Article
Open AccessVimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer
High circulating tumor cell (CTC) counts are associated with poor prognosis in advanced prostate cancer, and recently CTC number was suggested to be a surrogate for survival in metastatic castrate-resistant pr...
-
Article
Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party
Little is known about the prognostic impact of prior paclitaxel therapy and response to induction chemotherapy defined as the regimen preceding high-dose chemotherapy (HDCT) for the salvage therapy of advanced...
